Key Highlights

  • Shares trading up 2.44% pre-market, adding $2.83 to reach $118.93
  • Move extends a partial recovery after shares fell 6.68% Tuesday despite a fiscal third-quarter Earnings beat
  • Fiscal Q3 2026 Revenue of $118.4 million beat the $114.5 million estimate, up 23% year-over-year
  • Adjusted EPS loss of $0.56 was wider than the $0.50 loss analysts expected
  • Raised full-year fiscal 2026 total revenue guidance to $456 million to $457 million
  • Tuesday's decline coincided with a broad risk-off tone in equities as Treasury yields surged to their highest since 2007

Shares Extend Partial Recovery From Tuesday's Pullback

Twist Bioscience (NASDAQ:TWST) shares are trading up 2.44% in pre-market action Wednesday to $118.93, giving back a chunk of Tuesday's decline after the stock had pushed to a near 52-week high following strong fiscal third-quarter results. The company reported revenue of $118.4 million, beating the $114.5 million estimate and up 23% year-over-year, marking its 14th consecutive quarter of sequential growth, though the adjusted EPS loss of $0.56 was wider than the $0.50 loss analysts had expected.

Twist Bioscience Corporation, founded in 2013 and headquartered in South San Francisco, California, is a synthetic biology and genomics company that has pioneered a proprietary, silicon-based DNA synthesis platform for writing DNA directly onto semiconductor chips. Through this technology, the company manufactures a broad portfolio of synthetic DNA-based products, including custom synthetic genes, oligo pools, next-generation sequencing sample preparation tools, and antibody libraries used in biopharmaceutical drug discovery, serving customers across healthcare, diagnostics, agriculture, industrial chemicals, and academic research.

Beat Overshadowed by Broader Risk-Off Tone

Tuesday's decline coincided with a broad risk-off tone across equities as surging Treasury yields, near a 5.3% high not seen since 2007, and rising oil prices amid escalating Middle East tensions weighed on the Nasdaq, down over 1%, though healthcare broadly outperformed tech. Investors also continued digesting insider selling, including CEO Emily Marine Leprousts's roughly $17.7 million sale over the prior 90 days, alongside a backdrop of continued institutional buying, such as Bank of America boosting its stake by 46.3% in the first quarter.

The company raised full-year fiscal 2026 total revenue guidance to $456 million to $457 million, about 21% growth year-over-year, expecting growth in both DSPS and NGS segments, and adjusted EBITDA breakeven in the fourth fiscal quarter of 2026 and continued profitability expansion into fiscal 2027. Management reaffirmed confidence in meeting or exceeding triple-digit percentage order growth for AI-enabled drug discovery in fiscal 2026, and highlighted competitive advantages including its semiconductor-based DNA synthesis platform, with new complex genes product launch, over 1,800 genes across 100-plus orders during early sales, Manufacturing cost reductions of 60% lower costs, 70% less waste, and 73% faster turnaround compared to three years earlier, and an expanding total addressable market projected to reach $13 billion by 2030.

Conclusion

Twist Bioscience's (NASDAQ:TWST) pre-market gain reflects a partial recovery from Tuesday's broader risk-off selloff, which occurred despite a fiscal third-quarter beat on revenue and raised full-year guidance. With the company targeting adjusted EBITDA breakeven in the fourth quarter and continued profitability expansion into fiscal 2027, the stock's next moves will likely hinge on whether AI-enabled drug discovery order growth can sustain the momentum management has guided toward.